[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo Updates
September 12, 2001

Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma

Author Affiliations

Author Affiliations: Duke University Medical Center, Department of Medicine, Division of Oncology and Bone Marrow Transplantation, Durham, NC.

 

Contempo Updates Section Editors: Alice T. D. Hughes, MD; Janet M. Torpy, MD, Fishbein Fellows.

JAMA. 2001;286(10):1149-1152. doi:10.1001/jama.286.10.1149

Monoclonal antibodies are revolutionizing the treatment of many illnesses. Some patients with coronary artery disease, Crohn disease, solid organ transplants, rheumatoid arthritis, or cancer have already experienced benefits from these engineered proteins. Monoclonal antibodies typically either harness the patient's own immune system to fight disease or suppress an errant immune system. Table 1 lists the monoclonal antibodies currently approved by the Food and Drug Administration (FDA); more than 50 others are in active clinical trials around the world. Monoclonal antibodies are currently used by cardiologists, gastroenterologists, nephrologists, and rheumatologists as well as oncologists. In this article, we focus on the use of monoclonal antibodies for the treatment of patients with non-Hodgkin lymphoma (NHL).

First Page Preview View Large
First page PDF preview
First page PDF preview
×